Sarcoidosis 的个性化药物:解开针对性护理的生物标志物
Joel Francesqui1,2, Pau Marrades2, Jacobo Sellares2
1Pulmonology Department, Hospital General de Granollers.
Current opinion in pulmonary medicine
|July 6, 2023
概括
这篇综述探讨了沙尔科毒症的新生物标志物,这是一个具有诊断挑战的疾病. 影像和奥米克学的进步为更好的诊断和个性化治疗策略提供了希望.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- Sarcoidosis 的诊断是具有挑战性的,需要改进的工具.
- 目前的生物标志物如ACE和sIL-2R的准确性有限.
- 需要可靠的生物标志物来指导沙尔科病的临床决策.
研究的目的:
- 评估目前和新兴的类菌病生物标志物.
- 解决对增强诊断,预后和管理工具的需求.
- 审查了对型硬化症生物标志物发现的进展.
主要方法:
- 关于已确定的和新鲜的 Sarcoidosis 生物标志物的文献综述.
- 分析基因表达分析和奥米克学研究的发现.
- 在评估疾病活性时评估FDG-PET/CT成像.
主要成果:
- 已知生物标志物 (ACE,sIL-2R) 在敏感性和特异性方面存在局限性.
- FDG-PET/CT成像显示出评估疾病活性和指导治疗的潜力.
- 基因表达概况突出了TH1反应和IFN-γ通路作为潜在的生物标志物来源.
- 欧米克科学为在肉病中发现新的生物标志物提供了机会.
结论:
- 目前生物标志物的局限性需要进一步的研究,以改善 Sarcoidosis 诊断.
- 像FDG-PET/CT和omics这样的新兴技术为生物标志物开发提供了有前途的途径.
- 生物标志物发现的进步可以导致个性化的治疗策略和改善患者的治疗结果.
- 对新型生物标志物的持续验证对于在沙尔科毒症管理中的临床应用至关重要.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.5K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Structure-Activity Relationships and Drug Design
789
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
789